Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 95Carcinoma, Non-Small-Cell Lung 87Lung Neoplasms 21Squamous Cell Carcinoma of Head and Neck 19Melanoma 19Triple Negative Breast Neoplasms 14Stomach Neoplasms 13Breast Neoplasms 13Neoplasm Metastasis 11Head and Neck Neoplasms 11Carcinoma, Renal Cell 11Endometrial Neoplasms 10Urinary Bladder Neoplasms 9Neoplasms 9Carcinoma 9Carcinoma, Transitional Cell 7Carcinoma, Hepatocellular 7Colorectal Neoplasms 6Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Neoplasms by Site 4Esophageal Neoplasms 4Cholangiocarcinoma 4Thoracic Neoplasms 3Small Cell Lung Carcinoma 3Skin Neoplasms 3Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Lung Diseases 3

Interventions

osimertinib 3Vinorelbine 3Pemetrexed 3Cisplatin 3Carboplatin 3Gemcitabine 2Gefitinib 2Docetaxel 2CP protocol 2rezivertinib 1pembrolizumab 1aumolertinib 1Taxes 1Paclitaxel 1HMPL-013 1HM781-36B 1Erlotinib Hydrochloride 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × NSCLC × pembrolizumab × Clear all
NCT06754644 2025-06-10

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
808 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡